PL1807434T3 - Tienopirydyny jako allosteryczne środki wzmacniające receptor M4 muskarynowy - Google Patents

Tienopirydyny jako allosteryczne środki wzmacniające receptor M4 muskarynowy

Info

Publication number
PL1807434T3
PL1807434T3 PL05812144T PL05812144T PL1807434T3 PL 1807434 T3 PL1807434 T3 PL 1807434T3 PL 05812144 T PL05812144 T PL 05812144T PL 05812144 T PL05812144 T PL 05812144T PL 1807434 T3 PL1807434 T3 PL 1807434T3
Authority
PL
Poland
Prior art keywords
thienopyridines
muscarinic receptor
allosteric potentiators
potentiators
allosteric
Prior art date
Application number
PL05812144T
Other languages
English (en)
Inventor
Esteban Almudena Rubio
Darryl Wayne Hilliard
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL1807434T3 publication Critical patent/PL1807434T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
PL05812144T 2004-10-25 2005-10-18 Tienopirydyny jako allosteryczne środki wzmacniające receptor M4 muskarynowy PL1807434T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62178504P 2004-10-25 2004-10-25
EP05812144A EP1807434B1 (en) 2004-10-25 2005-10-18 Thienopyridines as allosteric potentiators of the m4 muscarinic receptor
PCT/US2005/037271 WO2006047124A1 (en) 2004-10-25 2005-10-18 Thienopyridines as allosteric potentiators of the m4 muscarinic receptor

Publications (1)

Publication Number Publication Date
PL1807434T3 true PL1807434T3 (pl) 2011-02-28

Family

ID=36021809

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05812144T PL1807434T3 (pl) 2004-10-25 2005-10-18 Tienopirydyny jako allosteryczne środki wzmacniające receptor M4 muskarynowy

Country Status (16)

Country Link
US (1) US8071776B2 (pl)
EP (1) EP1807434B1 (pl)
JP (1) JP4945453B2 (pl)
CN (1) CN100577666C (pl)
AT (1) ATE478876T1 (pl)
AU (1) AU2005299957B2 (pl)
BR (1) BRPI0517438A (pl)
CA (1) CA2583550C (pl)
CY (1) CY1111477T1 (pl)
DE (1) DE602005023197D1 (pl)
DK (1) DK1807434T3 (pl)
ES (1) ES2349416T3 (pl)
MX (1) MX2007004794A (pl)
PL (1) PL1807434T3 (pl)
PT (1) PT1807434E (pl)
WO (1) WO2006047124A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126856A1 (en) * 2012-02-23 2013-08-29 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2014035829A1 (en) * 2012-08-31 2014-03-06 Vanderbilt University Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators
EA201690089A1 (ru) 2013-06-11 2017-04-28 Латвийский Институт Органического Синтеза ТИЕНО[2,3-b]ПИРИДИНЫ КАК МОДУЛЯТОРЫ СОСТОЯНИЯ МНОЖЕСТВЕННОЙ ЛЕКАРСТВЕННОЙ УСТОЙЧИВОСТИ
US9637498B2 (en) 2013-08-23 2017-05-02 Vanderbilt University Substituted thieno[2,3-C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
ES2789756T3 (es) 2015-12-23 2020-10-26 Merck Sharp & Dohme Moduladores alostéricos de 6,7-dihidro-5H-pirrolo[3,4-b]piridin-5-ona del receptor de acetilcolina muscarínico M4
BR112018003417B1 (pt) 2016-06-22 2023-10-24 Vanderbilt University Composto modulador alostérico positivo do receptor muscarínico de acetilcolina m4 e composição farmacêutica que o compreende
HUE054857T2 (hu) 2016-07-01 2021-10-28 Pfizer 5,7-dihidro-pirrolo-piridinszármazékok neurológiai és neurodegeneratív betegségek kezelésére
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
US11008335B2 (en) 2016-11-07 2021-05-18 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4
US10927126B2 (en) 2016-11-07 2021-02-23 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4
CN109862893B (zh) 2016-11-07 2023-02-17 范德比尔特大学 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
CN110944998B (zh) 2017-06-22 2022-08-16 辉瑞大药厂 二氢-吡咯并-吡啶衍生物
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
JP2021505581A (ja) 2017-12-05 2021-02-18 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
WO2025201078A1 (zh) * 2024-03-25 2025-10-02 四川科伦药物研究院有限公司 化合物、包含其的药物组合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3430284A1 (de) * 1984-08-17 1986-02-27 Troponwerke GmbH & Co KG, 5000 Köln Neue tryptamin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung
RU2152385C1 (ru) * 1994-07-27 2000-07-10 Санкио Компани Лимитед Гетероциклические соединения, применимые в качестве аллостерических эффекторов при мускариновых рецепторах
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
GB9924962D0 (en) * 1999-10-21 1999-12-22 Mrc Collaborative Centre Allosteric sites on muscarinic receptors
RU2269523C2 (ru) * 2000-04-28 2006-02-10 Акадиа Фармасьютикалз, Инк. Мускариновые агонисты
WO2003072578A1 (en) * 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
US6974870B2 (en) * 2002-06-06 2005-12-13 Boehringer Ingelheim Phamaceuticals, Inc. Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses

Also Published As

Publication number Publication date
JP4945453B2 (ja) 2012-06-06
EP1807434B1 (en) 2010-08-25
ATE478876T1 (de) 2010-09-15
CA2583550A1 (en) 2006-05-04
CA2583550C (en) 2013-05-14
US8071776B2 (en) 2011-12-06
JP2008517913A (ja) 2008-05-29
ES2349416T3 (es) 2011-01-03
DK1807434T3 (da) 2010-11-22
WO2006047124A1 (en) 2006-05-04
AU2005299957B2 (en) 2011-04-21
BRPI0517438A (pt) 2008-10-07
MX2007004794A (es) 2007-07-09
DE602005023197D1 (de) 2010-10-07
CN101048413A (zh) 2007-10-03
CY1111477T1 (el) 2015-08-05
CN100577666C (zh) 2010-01-06
PT1807434E (pt) 2010-09-22
EP1807434A1 (en) 2007-07-18
AU2005299957A1 (en) 2006-05-04
US20090105244A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
MX2007004794A (es) Tienopiridinas como potenciadores alostericos del receptor muscarinico m4.
WO2007133802A3 (en) Pharmaceutical formulations of pimavanserin
WO2008040649A3 (en) Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
WO2008012622A3 (en) Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
WO2008077557A8 (en) 8-ethinylxanthine derivatives as selective a2a receptor antagonists
MY149869A (en) Thiophene derivatives as s1p1/edg1 receptor agonists
NO20085257L (no) Purinonderivater som HM74a-agonister
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
NO20085099L (no) Puritonderivativer som HM74A agonister
GB0504828D0 (en) Therapeutic agents
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
ATE399770T1 (de) Tachykininrezeptorantagonisten
MX2010002760A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3.
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
WO2010021882A3 (en) Cold menthol receptor antagonists
IL201317A0 (en) Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
WO2008045371A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
MX2009003382A (es) Derivados de sulfonamidas sustituidos.
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
MXPA05012082A (es) Compuestos como antagonistas del receptor crf1.
WO2006023757A3 (en) Novel tricyclic, bicyclic, monocyclic, and acyclic amines as potent sodium channel blocking agents
TNSN07462A1 (en) Ampa receptor potentiators
MX2009006243A (es) Potenciadores del receptor ampa.